Preferred Label : Navicixizumab;
NCIt synonyms : Immunoglobulin G2-kappa, Anti-(Homo sapiens DLL4(delta-like 4)) and Anti-(Homo sapiens
VEGFA (Vascular Endothelial Growth Factor A,VEGF-a, VEGF)), Humanized and Chimeric
Monoclonal Antibody, Bispecific;
NCIt definition : A bispecific monoclonal antibody directed against both the Notch ligand delta-like
4 (DLL4) and the human tyrosine kinase vascular endothelial growth factor (VEGF),
with potential anti-angiogenic and antineoplastic activities. The anti-DLL4 moiety
of navicixizumab specifically binds to DLL4, prevents its interaction with Notch receptors,
and inhibits Notch-mediated signaling and gene transcription, which may both block
tumor angiogenesis and inhibit tumor cell growth. The anti-VEGF moiety binds to VEGF
and prevents the binding of VEGF to its receptor, which blocks VEGF-mediated signaling
and further inhibits the growth and maintenance of tumor blood vessels. The expression
of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is
required for the development of functional tumor blood vessels. The expression of
the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor
cell proliferation and invasion.;
UNII : 1W14T9L25W;
CAS number : 1638338-43-8;
Molecule name : OMP-305B83; OMP 305B83;
Origin ID : C119620;
UMLS CUI : C4519595;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
